Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Type:
Grant
Filed:
December 22, 2003
Date of Patent:
January 27, 2009
Assignee:
Celera Corporation
Inventors:
Michele Cargill, James J. Devlin, Olga Iakoubova
Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAST) and antibodies binds to PCAST. The present invention provides that PCAST is used as targets for screening agents that modulates the PCAST activities. Further the present invention provides methods for treating diseases associated with pancreas.
Type:
Grant
Filed:
December 1, 2006
Date of Patent:
April 15, 2008
Assignee:
Applera Corporation
Inventors:
Ian McCaffey, Kim Alving, Bruno Domon, Steven Ruben
Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary stenosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Abstract: The subject matter of the invention concerns three cosmid vectors which are suitable for fragment cloning of a size between 7 and 36 kb. These vectors consist of an E. coli ColE1 replica, an ampicillin resistance gene, a multiple cloning cassette, cos sites for in vitro packaging with the lambda packaging extracts as well as fragments from the genome of the bacteriophage lambda. The lambda sequences were selected in a way to prevent lytic processes, vector instabilities (deletions) and unwanted recombination events between lambda DNA and the fragment to be cloned. Depending on the length of the lambda fragment inserted in the corresponding vector heterologous fragments of different lengths can be cloned.
Type:
Grant
Filed:
November 17, 1998
Date of Patent:
December 19, 2000
Inventors:
Thomas Metzler, Harald Sobek, Rolf Reichhuber
Abstract: 2'-Deoxyisoguanosine, isosteric analogues and isoguanosine derivatives of formulae I-V, processes for their production via compounds of the general formulae a or b and reaction with aroyl isocyanates or from compounds of the general formulae VI-IX by photochemical irradiation. A further production process is the conversion of deoxyguanosines or guanosines by means of persilylation, reaction with ammonia and deamination in the 2 position. The compounds are suitable as pharmaceutical agents with antiviral efficacy.
Type:
Grant
Filed:
May 29, 1998
Date of Patent:
November 14, 2000
Assignee:
Boehringer Mannheim
Inventors:
Frank Seela, Zigmunt Kasimierczuk, Klaus Muhlegger, Herbert Von Der Eltz